Rapidly expanding globalisation enabled us to strengthen our international presence to take new and complex challenges with flexibility, passion, discipline and creativity.
The group comprises several companies in Germany as well as more than 20 subsidiaries and joint ventures around the world. International business represents roughly half of the total group turnover and contributes significantly to the company’s growth strategy. The Schwabe Group is presently expanding its marketing activities in five continents. We adapt to the changing regulatory needs and have achieved thousands of drug registrations world-wide. Today, our products are available in over 60 countries either through Schwabe’s own companies and joint ventures or through licence partners. As a 100% privately-held independent company we offer both, exceptional flexibility and swift decision making. We enjoy a strong record in establishing and maintaining successful business relations with our partners. We know that sharing of information is essential to maintain people’s confidence. Schwabe’s International Division ensures reliable and fast communication of both business and scientific topics and serves as the primary point of contact for our international customers. We are delighted to work with our partners in healthcare around the world.
Expansion of the organisation had started soon after its foundation. In 1898 itself, the first company in abroad was founded in Amsterdam, the Netherlands. Our company’s share in the European, Asian and American markets has been increasing especially since the 1980s. It entered into the Mexican market in 1980 via the company Farmasa. In 1982 the company set up its own Ginkgo plantations in France and the United States. In 1985, Spitzner pharmaceuticals was acquired in the homeland Germany itself. During the period between 1985 and 1991, the group had acquired many companies in countries like Italy, Switzerland, Spain, Germany and the US. In 1992 Schwabe Pharma AG was founded in Switzerland. In the same year, Schwabe entered the US herbal medicine market via Nature’s Way, Inc. Dr. Willmar Schwabe India Pvt. Ltd. was founded and Schwabe became stakeholder of Austroplant Arzneimittel GmbH, Austria in 1994. Schwabe invested its own companies in China and Russia from 1996 to 1999. Subsidiaries are founded in the Czech Republic, Slovakia and Hungary during the period between 2000 and 2003. In 2004, Nature’s Way of Canada Ltd. was founded. In Singapore, Schwabe Pharma Asia Pacific Pte. Ltd. started operating from 2005. In the year 2006, there was another acquisition in the US by purchasing Abkit Inc. ASI Romania started operations in 2007. In the United Kingdom, Schwabe acquired MH Pharma in 2008. In the same year, the organisation has signed a contract through its subsidiary, Nature’s Way to purchase all outstanding shares of Enzymatic Therapy from North Castle Partners, LLC. In 2009 it announced the acquisition of Dr. Peithner Holding GmbH, Vienna, Austria.